InsiderTrades.com logo
Charles N. York, II net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Charles York, II Biography and Net Worth

Chief Operating and Financial Officer of Day One Biopharmaceuticals

Charles York II, M.B.A. joined Day One in 2021 and brings more than 20 years of corporate finance experience to the Company. In both public and private enterprises in the biotechnology industry, he has held transactional and strategic capital formation roles, including operations, corporate, and business development.

Previously, Mr. York served as Chief Financial Officer and Head of Corporate Development at Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease, where he led capital formation and allocation, investor relations and corporate development from 2015 – 2021, after joining the company as Vice President, Finance in July 2014. Mr. York has held multiple financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP.  

Mr. York is a CPA in the state of Arizona. He received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.

What is Charles N. York, II's net worth?

The estimated net worth of Charles N. York, II is at least $2.46 million as of November 17th, 2025. Mr. York, II owns 294,715 shares of Day One Biopharmaceuticals stock worth more than $2,457,923 as of December 4th. This net worth estimate does not reflect any other assets that Mr. York, II may own. Learn More about Charles N. York, II's net worth.

How do I contact Charles N. York, II?

The corporate mailing address for Mr. York, II and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Charles N. York, II's contact information.

Has Charles N. York, II been buying or selling shares of Day One Biopharmaceuticals?

Over the course of the past ninety days, Charles N. York, II has sold $36,192.42 in shares of Day One Biopharmaceuticals stock. Most recently, Charles N. York II sold 4,062 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a transaction totalling $36,192.42. Following the completion of the sale, the chief financial officer now directly owns 294,715 shares of the company's stock, valued at $2,625,910.65. Learn More on Charles N. York, II's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Jeremy Bender (CEO), Samuel Blackman (Insider), Adam Dubow (General Counsel), Papanek Grant (Director), Lauren Merendino (Insider), Saira Ramasastry (Director), and Charles York, II (Chief Operating and Financial Officer). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 134,085 shares worth more than $1,259,570.00. The most recent insider tranaction occured on November, 17th when insider Adam Dubow sold 4,319 shares worth more than $38,482.29. Insiders at Day One Biopharmaceuticals own 6.2% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 11/17/2025.

Charles N. York, II Insider Trading History at Day One Biopharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2025Sell4,062$8.91$36,192.42294,715View SEC Filing Icon  
8/18/2025Sell4,106$6.77$27,797.62278,000View SEC Filing Icon  
5/16/2025Sell4,282$6.26$26,805.32265,231View SEC Filing Icon  
2/18/2025Sell4,370$11.96$52,265.20252,638View SEC Filing Icon  
8/16/2024Sell2,633$14.00$36,862.00232,485View SEC Filing Icon  
5/16/2024Sell2,675$16.08$43,014.00224,868View SEC Filing Icon  
5/3/2024Sell8,078$17.85$144,192.30217,293View SEC Filing Icon  
5/1/2024Sell52,183$17.89$933,553.87225,571View SEC Filing Icon  
2/16/2024Sell2,666$15.25$40,656.50277,754View SEC Filing Icon  
11/16/2023Sell956$11.69$11,175.64270,170View SEC Filing Icon  
8/17/2023Sell922$13.86$12,778.92267,501View SEC Filing Icon  
5/16/2023Sell955$13.12$12,529.60264,798View SEC Filing Icon  
2/16/2023Sell930$19.57$18,200.10271,505View SEC Filing Icon  
1/20/2023Sell10,000$22.75$227,500.00268,810View SEC Filing Icon  
12/20/2022Sell10,000$20.07$200,700.00276,497View SEC Filing Icon  
11/21/2022Sell10,000$20.76$207,600.00286,497View SEC Filing Icon  
11/16/2022Sell430$21.46$9,227.80296,497View SEC Filing Icon  
11/1/2022Sell10,000$20.03$200,300.00294,401View SEC Filing Icon  
10/3/2022Sell10,000$20.05$200,500.00304,401View SEC Filing Icon  
8/16/2022Sell1,089$24.31$26,473.59324,401View SEC Filing Icon  
8/4/2022Sell10,000$20.05$200,500.00321,365View SEC Filing Icon  
7/18/2022Sell2,500$20.00$50,000.00331,365View SEC Filing Icon  
7/8/2022Sell1,416$20.00$28,320.00333,865View SEC Filing Icon  
7/5/2022Sell800$20.00$16,000.00335,281View SEC Filing Icon  
7/1/2022Sell1,479$20.00$29,580.00336,081View SEC Filing Icon  
See Full Table

Charles N. York, II Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Charles N York II's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $8.34
Low: $8.21
High: $8.60

50 Day Range

MA: $8.08
Low: $6.77
High: $10.36

2 Week Range

Now: $8.34
Low: $5.64
High: $13.92

Volume

2,072,215 shs

Average Volume

2,762,046 shs

Market Capitalization

$856.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A